


*Dal caso clinico
alle nuove strategie
terapeutiche:
confronto tra Cardiologi Ospedalieri
e Medici di Medicina Generale*

Responsabili del Convegno:

Dott. Ferdinando Varbella, Dott. Riccardo Riccardi,
Dott.ssa Maria Milano



- invito a:
- Medici di Medicina Generale
 - Cardiologi

Sabato 23 Settembre 2017

IL MULINO DI PIOSSASCO

Sala Teatro

Via Riva Po 9 - Piossasco (TO)

crediti
ECM

ARITMIE ED ABLAZIONE

GLI SVENIMENTI DEL Sig. MONALITO

Dr.ssa Elisa Favro


Dr. Antonio Mazza

Dr.ssa Maria Milano

Giunge in studio paziente maschio di 38 anni normoteso, non familiarità per cardiopatia nè precedenti patologici remoti, riferendo un episodio sincopale sul posto di lavoro in ortostatismo preceduto da fugaci prodromi

Clinicamente iperpiressia da sindrome flogistica alte vie respiratorie da 3 giorni in assenza di terapia

Avete la possibilità di eseguire un ECG :





primo snodo

- Ipotesi 1 sindrome coronarica acuta sopra ST
- Ipotesi 2 sincope ipotensiva ortostatica in contesto flogistico
- Ipotesi 3 sincope aritmica slatentizzata da extrasistolia ventricolare

Le extrasistoli ventricolari sono sempre un indicatore prognostico negativo?

NO se...

- Rare
- Monomorfe
- Non precoci
- Isolate
- Assenza di cardiopatia strutturale/
aritmogena







Potenzialmente " non benigne" ...

- Polimorfe
- Numerose
- Fenomeni ripetitivi

Riepilogo					
Numeri Referto : 8412037E10B3200	Ora Inizio : 14.20.00	Battiti Totali : 106560			
Data Test : 02/02/2017	Ore Analizzate : 21 : 10 : 55	Battiti sconosciuti : 76			
Data Referto : 03/02/2017	Artefatti : 0 : 02 : 26	Altri Battiti : 0			
Frequenza	Eventi frequenza dipendenti				
Min : 60 BPM alle 02.15.00-2 salve Bradicardia			Pause : 0		
Max : 127 BPM alle 07.04.00-2 Più lunga			Più lunga : 60 sec.		
Med : 83 BPM Freq. min.			alle		
Associate a segni di cardiopatia strutturale (ischemica, cardiomiopatia ipertrofica, displasia aritmogena, cardiomiopatia dilatativa...) o a malattia dei canali ionici, "channelopathy".					
Battiti Totali : 15201	Eventi Ventriculari : Coppie : 2584	Battiti Totali : 267	Eventi Supraventricolari : 0		
% battiti : 42,42	Triplett : 678	% battiti : 0,27			
Forme : 110	Salve brevi : 710				
Salve AlVR/IVR : 3					
Più lunga : 3 batt. alle 18.18.07-1					
Freq. Min : 84 BPM 20.07.22-1					
Salve Tachi V : 1077					
Più lunga : 11 batt. alle 19.51.22-1					
Freq. Max : 196 BPM 14.28.57-1					
VE/minuto max : 76 batt. alle 06.52.00-2					
VE/ora max : 3165 beatt. 07.00.00-2					
VE/ora medio : 2152,4					
VE/1000 : 424,2					

Impressioni e Note






Secondo snodo

Abbiamo visto l'extrasistolia ventricolare ed analizzato il qrs-t

1. È normale che l' intervallo QT allunghi dopo extrasistole
2. Conta più la ripetitività della morfologia dell' extrasistolia
3. sopra ST solo in V₁₋₂ non è compatibile con lesione ischemica
4. Le anomalie concordano con una patologia unificante



PA 180/ 90


BRUCE

PA 180/ 90

BRUCE
Post 04:59

STADIO 03
METS 1.0
Vel. 0.0 km/h
Gradi 0.0 %
Timer 01:59

km/h
%



(G Ital Cardiol 2010; 11 (11 Suppl 2): 35-225)

Consensus Conference promossa dalla Società Italiana di Cardiologia

Giuseppe Oreto¹, Domenico Corrado², Pietro Delise³, Francesco Fedele⁴, Fiorenzo Gaita⁵,
Federico Gentile⁶, Carla Giustetto⁵, Antonio Michelucci⁷, Luigi Padeletti⁷, Silvia Priori⁸

Makimoto et al JAAC 2010;56:15



terzo snodo

Quale terapia in attesa del cardiologo


- 1 Antipiretico e antibiotico
- 2 Beta bloccante a scopo sintomatico
- 3 Antiaritmico - es. Propafenone
- 4 Ansiolitici

Brugada Syndrome: Diagnosis

Brugada Syndrome is diagnosed in patients with ST-segment elevation with type I morphology $\geq 2\text{mm}$ in ≥ 1 lead among the right precordial leads V1 and/or V2 positioned in the 2nd, 3rd or 4th intercostal space, occurring either spontaneously or after provocative drug test with intravenous administration of sodium channel blockers (such as ajmaline, flecainide, procainamide or pilsicainide).





Type 1 pattern




Brugada Syndrome (BrS)

- Prevalence up to 1 in 1,000.
- Autosomal dominant inheritance, but age and gender-related penetrance (males:females ratio 8:1).
- 41+15 years mean age at CA.
- VF occurs mainly during rest or sleep.
- Fever is a triggers that predispose to VF.
- At least 12 genes have been associated with Brugada syndrome, only two (SCN5A and CACN1Ac) account for >5% of genotyped patients.



ipotesi di sincope aritmica in s.Brugada tipo 1 spontaneo



Recommendations	Class ^a	Level ^b
Indications		
• In patients with ischaemic heart disease EPS is indicated when initial evaluation suggests an arrhythmic cause of syncope (listed in Table 10) unless there is already an established indication for ICD	I	B
• In patients with BBB, EPS should be considered when non-invasive tests have failed to make the diagnosis	IIa	B
• In patients with syncope preceded by sudden and brief palpitations, EPS may be performed when other non-invasive tests have failed to make the diagnosis	IIb	B
• In patients with Brugada syndrome, ARVC and hypertrophic cardiomyopathy an EPS may be performed in selected cases	IIb	C
• In patients with high-risk occupations, in whom every effort to exclude a cardiovascular cause of syncope is warranted, an EPS may be performed in selected cases	IIb	C
• EPS is not recommended in patients with normal ECG, no heart disease, and no palpitations	II	B
Diagnostic criteria		
• EPS is diagnostic, and no additional tests are required, in the following cases:		
<input type="checkbox"/> Sinus bradycardia and prolonged CSNRT (>525 ms)	I	B
<input type="checkbox"/> BBB and either a baseline HV interval of ≥ 100 ms, or second or third degree His–Purkinje block is demonstrated during incremental atrial pacing, or with pharmacological challenge	I	B
<input type="checkbox"/> Induction of sustained monomorphic VT in patients with previous myocardial infarction	I	B
<input type="checkbox"/> Induction of rapid SVT which reproduces hypotensive or spontaneous symptoms	I	B
• An HV interval between 70 and 100 ms should be considered diagnostic	IIa	B
• The induction of polymorphic VT or ventricular fibrillation in patients with Brugada syndrome, ARVC, and patients resuscitated from cardiac arrest may be considered diagnostic	IIb	B
• The induction of polymorphic VT or ventricular fibrillation in patients with ischaemic cardiomyopathy or DCM cannot be considered a diagnostic finding	III	B

EUROPEAN
SOCIETY OF
CARDIOLOGY[®]European Heart Journal (2009) 30, 2631–2671
doi:10.1093/euroheartj/ehp298

ESC GUIDELINES



Guidelines for the diagnosis and management of syncope (version 2009)

The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC)

BrS: Lifestyle modifications for all patients (class I)

- Avoidance of drugs that may induce type I pattern

www.brugadadrugs.org

BrugadaDrugs.org

Safe drug use and the Brugada syndrome


- Avoidance of excessive alcohol intake and large meals



- Prompt treatment of any fever





Studio elettrofisiologico intravacitario





BrS: Implantable Cardioverter Defibrillator

- The only treatment able to reduce the risk of SCD in Brugada syndrome is the ICD...Who does need it?

ICD implantation is recommended in patients with a diagnosis of Brugada syndrome who: a. Are survivors of an aborted cardiac arrest, and/or b. Have documented spontaneous sustained VT.	I	C
ICD implantation should be considered in patients with a spontaneous diagnostic type I ECG pattern and history of syncope.	IIa	C
ICD implantation may be considered in patients with a diagnosis of Brugada syndrome who develop VF during PVS with up to either 2 or 3 extrastimuli at two sites.	IIb	C






BrS: additional therapeutic options

Quinidine or isoproterenol should be considered in patients with Brugada syndrome to treat electrical storms.	IIa	C
Quinidine should be considered in patients who qualify for an ICD, but present a contra-indication or refuse it, and in patients who require treatment for supraventricular arrhythmias.	IIa	C
Catheter ablation may be considered in patients with a history of electrical storms or repeated appropriate ICD shocks.	IIb	C





Concetti da asporto

Take home message

- LA MORFOLOGIA DELL' EXTRASISTOLE VA SEMPRE CONTESTUALIZZATA CON LA PATOLOGIA DI BASE
- UNA MORFOLOGIA «BENIGNA» O MONOMORFA NON INDICA NECESSARIAMENTE BASSA PERICOLOSITA'
- ANALIZZARE ATTENTAMENTE IL QRS-T PERCHE' QUESTO DETERMINA IL PESO PROGNOSTICO DELL' EXTRASISTOLE
- NON PRESCRIVERE BETA BLOCCANTI NE' ANTIARITMICI «INDIPENDENTEMENTE» E MAI PRIMA DI AVERE FATTO DIAGNOSI DI CARDIOPATIA SOTTOSTANTE

10 mm/mV

10 mm/mV



**GRAZIE
PER L'ATTENZIONE**

